GlassScriptPhysician profile
Lucas Schnaidt
NPI 1477114098
$4,449.93
in general payments reported to CMS, 2019-2025
19 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $113 · 2021: $145 · 2022: $517 · 2023: $725 · 2024: $972 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,753 · Travel and Lodging: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.29 |
| Travel and Lodging | $922.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,226.37 | 2022-2025 | Unity, Clareon, Hydrus Microstent |
| Abbvie INC. | $382.65 | 2023-2025 | Durysta |
| Horizon Therapeutics Plc | $359.20 | 2021-2023 | Tepezza |
| Glaukos Corporation | $296.38 | 2023-2025 | Idosetr, Istent Infinite, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $230.37 | 2025 | Healon Duet Pro |
| Galderma Laboratories, L.P. | $146.09 | 2022 | |
| Amgen INC. | $122.07 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $117.15 | 2023 | Omni Surgical System |
| Allergan, INC. | $112.74 | 2020 | |
| Genentech USA, INC. | $110.53 | 2024-2025 | Vabysmo |
| New World Medical,INC. | $105.66 | 2023 | |
| Rxsight INC | $57.37 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Rayner Intraocular Lenses Limited | $50.64 | 2025 | Omidria |
| Biotissue Holdings INC. | $35.01 | 2025 | |
| Ani Pharmaceuticals, INC. | $24.88 | 2025 | Iluvien |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $21.77 | 2024 | Oxervate |
| Genzyme Corporation | $19.89 | 2021 | |
| Ocular Therapeutix, INC. | $19.14 | 2025 | Dextenza |
| Align Ophthalmics LLC | $12.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucas Schnaidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.